<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00553787</url>
  </required_header>
  <id_info>
    <org_study_id>OB-303</org_study_id>
    <nct_id>NCT00553787</nct_id>
  </id_info>
  <brief_title>Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions</brief_title>
  <official_title>A Phase III Randomized, Double-Blind, Placebo Controlled Multicenter Study to Determine the Safety and Efficacy of VI-0521 in the Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VIVUS, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VIVUS, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of VI0521 compared to
      placebo in treatment of obesity in an adult population with obesity related co-morbid
      conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Weight Loss From Baseline to Week 56</measure>
    <time_frame>Baseline to 56 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With a Weight Loss of at Least 5% at Week 56 With LOCF</measure>
    <time_frame>Baseline to 56 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2487</enrollment>
  <condition>Obesity</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>VI-0521 Top</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose experimental treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VI-0521 Mid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mid dose experimental treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VI-0521</intervention_name>
    <description>phentermine 15 mg and topiramate 92 mg, po once daily</description>
    <arm_group_label>VI-0521 Top</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VI-0521</intervention_name>
    <description>phentermine 7.5 mg and topiramate 46 mg, po once daily</description>
    <arm_group_label>VI-0521 Mid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VI-0521</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed Consent

          -  BMI ≥ 27 (no lower BMI limit for Type 2 diabetics)

          -  70 years of age or less

          -  Have 2 or more of the following obesity-related co-morbid conditions:

               -  Systolic blood pressure 140-160 mmHg (130-160 if diabetic);

               -  Diastolic blood pressure 90-100 mmHg (85-100 if diabetic);

               -  Requirement for 2 or more medications to achieve control (&lt;140/90 mmHg)

          -  Triglyceride level between 200-400 mg/dL or requirement for 2 or more medications to
             achieve control (&lt;200 mg/dL)

          -  At lease one of the following metabolic criteria:

               -  Fasting blood glucose level &gt; 100 mg/dL

               -  Glucose level &gt; 140 mg/dL

               -  Diagnosis of type 2 diabetes

          -  Waist circumference ≥ 102 cm for men or ≥88 cm for women

        Exclusion Criteria:

          -  Stroke/MI/unstable cardiovascular disease within 6 months

          -  Clinically significant renal, hepatic or psychiatric disease

          -  Unstable thyroid disease or replacement therapy

          -  Nephrolithiasis

          -  Obesity of known genetic or endocrine origin

          -  Participation in a formal weight loss program or lifestyle intervention

          -  Glaucoma or intraocular pressure

          -  Pregnancy or breastfeeding

          -  Drug or Alcohol abuse

          -  Smoking cessation within previous 3 months or plans to quit smoking during study

          -  Eating disorders

          -  Cholelithiasis within past 6 months

          -  Excluded medications

          -  Type 1 diabetes or use of any antidiabetic medication other than metformin

          -  Previous bariatric surgery

          -  Bipolar disorder or psychosis

          -  Steroid hormone therapy

          -  Systolic blood pressure &gt; 160 mmHg, diastolic blood pressure &gt; 100 mmHg

          -  Creatinine clearance &lt; 60 mL/minute
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Peterson</last_name>
    <role>Study Director</role>
    <affiliation>VIVUS, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kishore Gadde, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ridgefield</city>
        <state>Connecticut</state>
        <zip>06877</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2007</study_first_submitted>
  <study_first_submitted_qc>November 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2007</study_first_posted>
  <results_first_submitted>July 31, 2012</results_first_submitted>
  <results_first_submitted_qc>July 31, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 6, 2012</results_first_posted>
  <disposition_first_submitted>November 30, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>November 30, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 2, 2009</disposition_first_posted>
  <last_update_submitted>September 5, 2012</last_update_submitted>
  <last_update_submitted_qc>September 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity, Type 2 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subject recruitment occurred at investigative sites in the US between November 2007 through May 2008</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
        </group>
        <group group_id="P2">
          <title>VI-0521 Mid</title>
          <description>7.5 mg/46 mg phentermine/topiramate</description>
        </group>
        <group group_id="P3">
          <title>VI-0521 Top</title>
          <description>15 mg/92 mg phentermine/topiramate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="994"/>
                <participants group_id="P2" count="498"/>
                <participants group_id="P3" count="995"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="616"/>
                <participants group_id="P2" count="374"/>
                <participants group_id="P3" count="733"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="378"/>
                <participants group_id="P2" count="124"/>
                <participants group_id="P3" count="262"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="67"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="78"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="83"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non compliance</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Requirement for restricted medication</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
        </group>
        <group group_id="B2">
          <title>VI-0521 Mid</title>
          <description>7.5 mg/46 mg phentermine/topiramate</description>
        </group>
        <group group_id="B3">
          <title>VI-0521 Top</title>
          <description>15 mg/92 mg phentermine/topiramate</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="994"/>
            <count group_id="B2" value="498"/>
            <count group_id="B3" value="995"/>
            <count group_id="B4" value="2487"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.2" spread="10.3"/>
                    <measurement group_id="B2" value="51.1" spread="10.4"/>
                    <measurement group_id="B3" value="51" spread="10.7"/>
                    <measurement group_id="B4" value="51.1" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="695"/>
                    <measurement group_id="B2" value="349"/>
                    <measurement group_id="B3" value="693"/>
                    <measurement group_id="B4" value="1737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="299"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="302"/>
                    <measurement group_id="B4" value="750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="994"/>
                    <measurement group_id="B2" value="498"/>
                    <measurement group_id="B3" value="995"/>
                    <measurement group_id="B4" value="2487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Weight Loss From Baseline to Week 56</title>
        <time_frame>Baseline to 56 weeks</time_frame>
        <population>intent-to-treat last-observation-carried-forward (ITT-LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>VI-0521 Mid</title>
            <description>7.5 mg/46 mg phentermine/topiramate</description>
          </group>
          <group group_id="O3">
            <title>VI-0521 Top</title>
            <description>15 mg/92 mg phentermine/topiramate</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Weight Loss From Baseline to Week 56</title>
          <population>intent-to-treat last-observation-carried-forward (ITT-LOCF)</population>
          <units>percent weight loss</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="979"/>
                <count group_id="O2" value="488"/>
                <count group_id="O3" value="981"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" spread="0.277"/>
                    <measurement group_id="O2" value="7.81" spread="0.365"/>
                    <measurement group_id="O3" value="9.84" spread="0.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With at least 500 subjects in each of the 3 arms in this trial, the trial has more than 90% power to detect a difference of at least 3.1% between combination and placebo treatment assuming a standard deviation of 5.3% and a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.328</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.96</ci_lower_limit>
            <ci_upper_limit>9.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>With at least 500 subjects in each of the 3 arms in this trial, the trial has more than 90% power to detect a difference of at least 3.1% between combination and placebo treatment assuming a standard deviation of 5.3% and a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.403</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.79</ci_lower_limit>
            <ci_upper_limit>7.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With at least 500 subjects in each of the 3 arms in this trial, the trial has more than 90% power to detect a difference of at least 3.1% between combination and placebo treatment assuming a standard deviation of 5.3% and a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.402</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.24</ci_lower_limit>
            <ci_upper_limit>2.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With a Weight Loss of at Least 5% at Week 56 With LOCF</title>
        <time_frame>Baseline to 56 weeks</time_frame>
        <population>intent-to-treat last-observation-carried-forward (ITT-LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>VI-0521 Mid</title>
            <description>7.5 mg/46 mg phentermine/topiramate</description>
          </group>
          <group group_id="O3">
            <title>VI-0521 Top</title>
            <description>15 mg/92 mg phentermine/topiramate</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With a Weight Loss of at Least 5% at Week 56 With LOCF</title>
          <population>intent-to-treat last-observation-carried-forward (ITT-LOCF)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="979"/>
                <count group_id="O2" value="488"/>
                <count group_id="O3" value="981"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8"/>
                    <measurement group_id="O2" value="62.1"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With at least 500 subjects in each of the 3 arms in this trial, the trial has more than 90% power to detect a difference of at least 3.1% between combination and placebo treatment assuming a standard deviation of 5.3% and a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>9.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.955</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.34</ci_lower_limit>
            <ci_upper_limit>11.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>With at least 500 subjects in each of the 3 arms in this trial, the trial has more than 90% power to detect a difference of at least 3.1% between combination and placebo treatment assuming a standard deviation of 5.3% and a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.768</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.93</ci_lower_limit>
            <ci_upper_limit>7.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With at least 500 subjects in each of the 3 arms in this trial, the trial has more than 90% power to detect a difference of at least 3.1% between combination and placebo treatment assuming a standard deviation of 5.3% and a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0018</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.169</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.15</ci_lower_limit>
            <ci_upper_limit>1.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected from when written informed consent was provided through 28 days after the last dose of investigational product.</time_frame>
      <desc>Only subjects who received at least one dose of study drug were included in the safety analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
        </group>
        <group group_id="E2">
          <title>VI-0521 Mid</title>
          <description>7.5 mg/46 mg phentermine/topiramate</description>
        </group>
        <group group_id="E3">
          <title>VI-0521 Top</title>
          <description>15 mg/92 mg phentermine/topiramate</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>myocardial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>goiter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>colitis ischemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>esophageal spasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>gastric ulcer hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>catheter related complications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>bursitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>anemia post-operative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>invtervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>arthraligia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>transient ischemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>brain mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>uterovaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>coital bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="761" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="424" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="874" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="173" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="207" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="133" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="98" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="85" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="101" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="204" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="99" subjects_at_risk="994"/>
              </event>
              <event>
                <sub_title>dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="103" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="993"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="498"/>
                <counts group_id="E3" subjects_affected="102" subjects_at_risk="994"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After Sponsor's written notification that publication of results is no longer planned or 12 months after termination of the study at all sites, Institution &amp; PI may publish, upon written approval from Sponsor, results of the Study. Sponsor will be given the opportunity to review any proposed publication at least 60 days prior to submission for publication or disclosure. Upon Sponsor's written request, Institution and PI shall not publish or disclose information related to the Study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wesley W Day PhD</name_or_title>
      <organization>Vivus, Inc</organization>
      <phone>650-934-5200</phone>
      <email>day@vivus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

